AstraZeneca PLC
AZN
$73.95
$0.861.18%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.98% | 94.40% | 4.97% | -25.84% | -11.56% |
| Total Depreciation and Amortization | 8.18% | 11.17% | -12.37% | 3.05% | 1.91% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -77.05% | -115.17% | -32.44% | 7,337.50% | 101.62% |
| Change in Net Operating Assets | 19.01% | -21.71% | -953.66% | 131.78% | 71.65% |
| Cash from Operations | -8.81% | 27.73% | -14.07% | 9.66% | 24.09% |
| Capital Expenditure | -53.61% | 39.41% | -69.78% | -9.16% | 8.39% |
| Sale of Property, Plant, and Equipment | 800.00% | -50.00% | -- | -- | -100.00% |
| Cash Acquisitions | 26.24% | -32.12% | -4.18% | 88.55% | -142.30% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -157.24% | -130.35% | 75.90% | -332.12% | 82.47% |
| Cash from Investing | -68.24% | -6.10% | 21.99% | 47.28% | -19.02% |
| Total Debt Issued | -41.40% | 292.13% | -37.83% | -127.63% | -74.87% |
| Total Debt Repaid | -35.29% | 28.57% | 94.30% | 23.05% | -3,248.15% |
| Issuance of Common Stock | -50.00% | -65.22% | 475.00% | -20.00% | -16.67% |
| Repurchase of Common Stock | 99.38% | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 99.70% | -111,466.67% | 99.81% | -9,170.59% | 99.44% |
| Other Financing Activities | -101.92% | -- | -100.00% | -- | 100.00% |
| Cash from Financing | 119.14% | -303.43% | 83.76% | -238.05% | -160.26% |
| Foreign Exchange rate Adjustments | 16.00% | 140.98% | -405.00% | 433.33% | 86.96% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 922.07% | -122.33% | 144.34% | -120.89% | -149.39% |